Uncategorized Archives - Page 131 of 134

TuesdayJul 07, 2020 3:30 pm

UK Company Secures Funds to Detect Epigenetic Cancer Signs

A University of Oxford spinout focusing on genomics will benefit from a seed round of $11.4 billion. It aims at improving cancer detection by measuring epigenetic changes to tumor DNA circulating in a patient’s blood. The oversubscribed seed funding round was pioneered by Oxford Sciences Innovation. It is a local early-stage investment enterprise connected to the University of Oxford. Base Genomics will make use of technology developed at the University of Oxford called TAPS. TAPS is responsible for detecting epigenetic methylation of DNA at a single-base level. DNA methylation is a method in which cells can switch off specific genes…

TuesdayJul 07, 2020 11:49 am

DarioHealth Corp. (NASDAQ: DRIO) is “One to Watch”

Dario’s popular (4.9 stars on the Apple App Store and 11,000 reviews) chronic condition management platform addresses a $72 billion annual U.S. market opportunity There are roughly 51,000 active users of the Dario platform, including its proprietary medical device, mobile application, and digital and human coaching services Clinical studies show Dario’s direct improvement on users’ health measures like H1AC scores (diabetes) and blood pressure (hypertension) Patient engagement in therapies leads to health success. The Dario platform centers on continual maximization of patient engagement through personalization, including ‘nudges’ and live, AI-generated responses to health measures provided by Dario smartphone-connected medical devices…

MondayJul 06, 2020 1:25 pm

Predictive Oncology Inc. (NASDAQ: POAI) Announces Acquisition of Soluble Therapeutics, BioDtech as it Continues Buildout of Precision Medicine Business

Predictive Oncology announced the acquisition of Soluble Therapeutics Inc. & BioDtech Inc. Acquired companies seek to enhance drug development process through the optimization of protein solubility and stability as well as through detection, removal of endotoxins The companies were acquired for consideration amounting to 125,000 common shares and waiving of $1.07 million promissory note issued by parent company, InventaBioTech Predictive Oncology seeks to build out its precision medicine business line, aimed at helping clinicians individualize cancer treatment Predictive Oncology (NASDAQ: POAI), a knowledge-driven medicine company that focuses on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug…

WednesdayJul 01, 2020 12:30 pm

Vivos Therapeutics, Inc. Non-Surgical, Non-Invasive, and Cost-Effective Solution, May Help Relieve OSA-Associated Healthcare Costs

Estimates suggest obstructive sleep apnea (“OSA”) costs the US economy $150 billion annually Medicare beneficiaries with obstructive sleep apnea cost taxpayers $19,566 per year Company’s oral appliances have shown to be effective in over 15,000 patients, successfully treated worldwide by approximately 1,250 trained dentists and doctors It is estimated that obstructive sleep apnea (“OSA”) affects approximately 1 billion people worldwide, of which 54 million are Americans (http://ibn.fm/jBfMi). According to a study published by the Journal of Clinical Sleep Medicine, individuals with untreated OSA face increased health care utilization (“HCU”) and costs across all service aspects. Costs and HCU were evaluated…

WednesdayJun 24, 2020 11:46 am

Vivos Therapeutics, Inc. Launches Promising Treatment of Mild to Moderate Obstructive Sleep Apnea in Adults

Obstructive Sleep Apnea (“OSA”) impacts up to 1 billion people globally, including 54 million Americans Estimates suggest OSA costs the U.S. economy $165 billion annually Vivos System offers significant advantages over traditional OSA treatment approaches Over 4,300 healthcare professionals registered for Vivos’ education and training Summit in March 2020, with strong and growing interest in this disruptive new technology Vivos Therapeutics’ Vivos System is the first treatment modality for mild to moderate OSA based on the ability to remodel and enhance the function, size, and shape of the human airway, in most cases avoiding the need for lifelong interventions. The…

WednesdayJun 17, 2020 12:49 pm

Vivos Therapeutics, Inc.’s Technology Offers Fresh Hope to Sleep Apnea Sufferers

Obstructive Sleep Apnea (“OSA”) is a pervasive disorder impacting the lives of up to 1 billion people globally and approximately 54 million Americans. OSA has been linked to increased rates of cancer, hypertension, cardiovascular disease, ADHD, Alzheimer’s, diabetes, dementia, and ultimately—up to 10-year shorter lifespans. Current front-line treatment options such as CPAP are intrusive and must be used every night for life in order to be effective. Surgical options and implants can be risky and expensive. The Vivos System is the first treatment modality for mild to moderate OSA which has demonstrated the ability to remodel and enhance the size,…

FridayJun 05, 2020 11:07 am

Vivos Therapeutics Inc. is “One to Watch”

Obstructive sleep apnea affects millions of people of all ages. It is estimated that OSA costs the US economy $165B annually. The Vivos technology represents the first non-surgical, non-invasive and cost-effective solution for the estimated hundreds of millions of people globally who suffer from OSA. As dentists have hundreds of patients of all ages suffering from OSA, the Vivos System presents a multi-million dollar revenue opportunity for dental practices. Vivos is helping address challenges throughout the world, reducing the overall cost of health care by focusing on a prevalent condition which is linked to many of the most expensive health…

ThursdayJun 04, 2020 11:45 am

Predictive Oncology Inc. (NASDAQ: POAI) CEO Discusses Acquisitions, Exclusive Database of Historical Tumor Data in Recent Interview

POAI boasts unique historical database documenting actual drug responses of tumors – the largest in the world with over 150,000 tumors across 137 types Drug discovery funding for subsidiary Helomics planned through relationships with large pharmaceutical companies Company planning to acquire two new biological firms in the precision medicine space Predictive Oncology Inc. (NASDAQ: POAI) is a knowledge-driven medicine company focused on applying data and artificial intelligence (AI) to cancer personalized medicine and drug discovery. In a recent interview (http://nnw.fm/o7Ysq), POAI director and CEO Dr. Carl Schwartz discussed the acquisition of two biological firms, along with details about the company’s…

TuesdayJun 02, 2020 12:34 pm

Predictive Oncology Inc.’s (NASDAQ: POAI) Subsidiary a ‘Major Asset’ in Growing Precision Medicine Space

POAI addresses pressing need for a multi-omic approach in field of precision medicine Global precision medicine market is expected to reach total market value of approximately $84 billion by 2026 Predictive Oncology’s ‘claim to fame’ is its inventory of over 150,000 tumors covering over 137 types of cancer, with over 30,000 related to ovarian cancer In the burgeoning world of precision medicine, Predictive Oncology Inc. (NASDAQ: POAI) appears ideally positioned to address one of the most pressing problems in the industry: the need for a multi-omic approach to precision therapy that may offer markedly improved patient outcomes over just genomics alone.…

FridayMay 22, 2020 12:06 pm

Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Helomics Leverages Cutting-Edge Tech and Datasets to Improve Cancer Outcomes

POAI subsidiary Helomics helps oncologists individualize cancer treatment using patient-derived tumor models to improve outcomes Helomics’ tumor genomic and drug response database is one of the largest in the world with over 150,000 tumors across 137 cancer types Expected CAGR of 10.3% from 2018-2024 for oncology segment of precision medicine industry The relationship between a patient and their cancer is personal: it’s specific, and it necessitates personalized treatment to be defeated effectively. Unfortunately, oncologists’ ability to personalize treatment for patients has largely been anything but, often resembling a trial-and-error method. This is largely because we have few targeted treatments or…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

UK Company Secures Funds to Detect Epigenetic Cancer Signs

DarioHealth Corp. (NASDAQ: DRIO) is “One to Watch”

Predictive Oncology Inc. (NASDAQ: POAI) Announces Acquisition of Soluble Therapeutics, BioDtech as it Continues Buildout of Precision Medicine Business

Vivos Therapeutics, Inc. Non-Surgical, Non-Invasive, and Cost-Effective Solution, May Help Relieve OSA-Associated Healthcare Costs

Vivos Therapeutics, Inc. Launches Promising Treatment of Mild to Moderate Obstructive Sleep Apnea in Adults

Vivos Therapeutics, Inc.’s Technology Offers Fresh Hope to Sleep Apnea Sufferers

Vivos Therapeutics Inc. is “One to Watch”

Predictive Oncology Inc. (NASDAQ: POAI) CEO Discusses Acquisitions, Exclusive Database of Historical Tumor Data in Recent Interview

Predictive Oncology Inc.’s (NASDAQ: POAI) Subsidiary a ‘Major Asset’ in Growing Precision Medicine Space

Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Helomics Leverages Cutting-Edge Tech and Datasets to Improve Cancer Outcomes

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search